OUR NEWS

Photograph: Ed Reschke / Getty Images

WIRED.com17 July 2023

A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It

THERE’S A MAJOR downside to semaglutide, the drug originally developed for diabetes and now prescribed for weight loss under the brand names Ozempic and Wegovy: People often stop...

BUSINESSWIRE.com26 June 2023

Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita^® in Open Label Phase of Revitalize 1...

BUSINESSWIRE.com

Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+ Telehealth Program...

Press Releases

Jan 18, 2022

Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

Jan 12, 2022

Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors

Nov 30, 2021

Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size

Oct 27, 2021

Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism

Sep 1, 2021

Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita^® DMR for Type 2 Diabetes

Jun 16, 2021

Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes

Apr 27, 2021

Fractyl Announces FDA Breakthrough Device Designation for Revita^® DMR in Insulin-Treated Type 2 Diabetes

- REVITA-T2Di study is underway to evaluate the effectiveness of Revita DMR in improving glucose control while reducing or eliminating the need for insulin -

Mar 22, 2021

Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita^® DMR for Type 2 Diabetes